3 Fermentation Ingredient, Biologics and Global Generic Stocks With a Strong Future Roadmap: Concord Biotech, Shilpa Medicare and Aurobindo Pharma
- October 14, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Concord Biotech Rs 1,369.70, P/E 51.00. Shilpa Medicare Rs 973.60, P/E 67.52. Aurobindo Pharma Rs 1,684.60, P/E 25.46. Closing prices of 13 Oct 2026.
Quick Answer
Fermentation ingredient, biologics and global generic stocks with the clearest long-term roadmaps today include Concord Biotech in fermentation-based active ingredients, including immunosuppressants and anti-infectives, Shilpa Medicare in active ingredients, formulations, biologics and contract manufacturing and Aurobindo Pharma in generic formulations and active ingredients sold in the US, Europe and emerging markets. P/E stands at 51.00 for Concord Biotech (industry 37.59), 67.52 for Shilpa Medicare (industry 37.59) and 25.46 for Aurobindo Pharma (industry 37.59). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Fermentation ingredient, biologics and global generic stocks give investors exposure to ingredients, advanced medicines and generics that drug makers and patients rely on. Volumes, export approvals and contract orders decide how much of that demand turns into profit.
This list covers three fermentation ingredient, biologics and global generic stocks: Concord Biotech for fermentation-based active ingredients, including immunosuppressants and anti-infectives, Shilpa Medicare for active ingredients, formulations, biologics and contract manufacturing and Aurobindo Pharma for generic formulations and active ingredients sold in the US, Europe and emerging markets. Every figure comes from the latest reported financials and the 13 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Fermentation Ingredient, Biologics and Global Generic Stocks?
Fermentation ingredient, biologics and global generic stocks are shares of companies that make ingredients, biologics and generic medicines. Results depend on volumes, export approvals and contract orders, so growth and margins separate the stronger names.
Fermentation Ingredient, Biologics and Global Generic Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three fermentation ingredient, biologics and global generic stocks as of the 13 Oct 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| Concord Biotech | 1,369.70 | 13,913 | 51.00 | 37.59 | 12.94% | 0.00 |
| Shilpa Medicare | 973.60 | 20,072 | 67.52 | 37.59 | 9.39% | 0.25 |
| Aurobindo Pharma | 1,684.60 | 94,477 | 25.46 | 37.59 | 9.25% | 0.21 |
Among healthcare stocks, Concord Biotech and Shilpa Medicare trade at a premium to the industry P/E, while Aurobindo Pharma trades at a discount.
Why Do Fermentation Ingredient, Biologics and Global Generic Stocks Have a Strong Roadmap in India?
Fermentation ingredient, biologics and global generic stocks have a strong roadmap in India because health spending, outsourced drug making and global demand for affordable generics keep lifting these businesses. Three drivers stand out.
- Ingredient demand: Global drug makers source from Indian fermentation plants.
- Advanced medicines: Biologics and contract work add higher-value revenue.
- Generic exports: Global buyers prefer affordable Indian medicines.
Concord Biotech: Fermentation Ingredients Drive the Pipeline
Concord Biotech’s roadmap rests on fermentation-based active ingredients, including immunosuppressants and anti-infectives, with regulated market exports supporting revenue.
Revenue grew from Rs 736.35 crore in FY22 to Rs 1,107.25 crore in FY26, a 50.4% rise. FY26 net profit was Rs 259.23 crore. In Q1 FY27, revenue grew 24.2% to Rs 270.32 crore, and net profit rose 31.0% to Rs 57.70 crore. Operating margin was 39.81% in FY26.
Debt to equity is 0.00 and return on equity is 12.94%. FY26 operating cash flow was Rs 266.88 crore against capital expenditure of Rs 95.15 crore. Concord Biotech paid a dividend of Rs 7.55 per share for FY26, a yield of 0.57%. At a P/E of 51.00 against an industry P/E of 37.59, the stock trades above its industry multiple.
What to watch: The P/E of 51.00 sits above the industry P/E of 37.59, so earnings delivery matters for the valuation.
Shilpa Medicare: Ingredients, Biologics and Formulations Anchor the Roadmap
Shilpa Medicare’s roadmap rests on active ingredients, formulations, biologics and contract development and manufacturing, with a wide product mix supporting revenue.
Revenue grew from Rs 1,159.77 crore in FY22 to Rs 1,548.71 crore in FY26, a 33.5% rise, and FY26 revenue was 18.2% higher than FY25. FY26 net profit was Rs 243.33 crore. In Q1 FY27, revenue grew 43.0% to Rs 468.91 crore. Operating margin was 30.79% in FY26 and 31.21% in Q1 FY27 against 30.26% a year earlier.
Debt to equity is 0.25 and return on equity is 9.39%. FY26 operating cash flow was Rs 342.18 crore against capital expenditure of Rs 370.63 crore. Shilpa Medicare paid a dividend of Rs 0.6 per share for FY26, a yield of 0.06%. At a P/E of 67.52 against an industry P/E of 37.59, the stock trades above its industry multiple.
What to watch: The P/E of 67.52 sits above the industry P/E of 37.59, so earnings delivery matters for the valuation.
Aurobindo Pharma: Generic Formulations and Ingredients Build the Next Leg
Aurobindo Pharma’s roadmap rests on generic formulations and active ingredients sold in the US, Europe and emerging markets, with a wide product basket supporting export revenue.
Revenue grew from Rs 23,775.84 crore in FY22 to Rs 34,145.17 crore in FY26, a 43.6% rise, and FY26 revenue was 5.6% higher than FY25. FY26 net profit rose 0.6% to Rs 3,502.97 crore. Over four years, net profit rose from Rs 2,647.11 crore in FY22 to Rs 3,502.97 crore. In Q1 FY27, revenue grew 18.1% to Rs 9,414.58 crore, and net profit rose 25.2% to Rs 1,032.03 crore. Operating margin was 21.61% in FY26 and 23.10% in Q1 FY27 against 21.95% a year earlier.
Debt to equity is 0.21 and return on equity is 9.25%. FY26 operating cash flow was Rs 5,526.37 crore against capital expenditure of Rs 3,104.67 crore. Aurobindo Pharma paid a dividend of Rs 4 per share for FY26, a yield of 0.25%. At a P/E of 25.46 against an industry P/E of 37.59, the stock trades below its industry multiple.
What to watch: Q1 FY27 operating margin was 23.10% against 21.61% for FY26, so margin stability is the figure to follow as volumes grow.
Best Fermentation Ingredient, Biologics and Global Generic Stocks in India: Concord Biotech vs Shilpa Medicare vs Aurobindo Pharma on Key Financials
Among the best fermentation ingredient, biologics and global generic stocks in India, Concord Biotech leads on FY26 operating margin and return on equity; Shilpa Medicare leads on Q1 FY27 revenue growth; Aurobindo Pharma leads on the lowest P/E. The table puts the numbers side by side.
| Metric | Concord Biotech | Shilpa Medicare | Aurobindo Pharma |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 1,107.25 | 1,548.71 | 34,145.17 |
| FY26 net profit (Rs Cr) | 259.23 | 243.33 | 3,502.97 |
| FY26 operating profit margin | 39.81% | 30.79% | 21.61% |
| Q1 FY27 revenue growth (YoY) | 24.2% | 43.0% | 18.1% |
| Return on equity | 12.94% | 9.39% | 9.25% |
| P/E ratio | 51.00 | 67.52 | 25.46 |
| Debt to equity | 0.00 | 0.25 | 0.21 |
| Dividend yield | 0.57% | 0.06% | 0.25% |
| FY26 operating cash flow (Rs Cr) | 266.88 | 342.18 | 5,526.37 |
Healthcare earnings follow volumes, export approvals and contract orders, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Fermentation Ingredient, Biologics and Global Generic Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen fermentation ingredient, biologics and global generic stocks and shortlist fermentation ingredient, biologics and global generic stocks to buy.
- Compare each stock’s P/E with its industry P/E, which is 37.59 for all three here.
- Check revenue growth, operating margin and return on equity together.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Risks to Consider Before Investing in Fermentation Ingredient, Biologics and Global Generic Stocks
- Valuation: Shilpa Medicare trades at 67.52 times earnings against an industry multiple of 37.59.
- Pricing rules: Export pricing can affect margins.
- Regulation: Plant inspections can affect supply.
- Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.
Download the Univest iOS App or Univest Android App to track Concord Biotech, Shilpa Medicare and Aurobindo Pharma live.
Annual reports and quarterly result presentations are the most reliable places to verify the numbers quoted here, because they show segment details, management commentary and the notes behind each figure.
Comparing a quarter with the same quarter of the previous year gives a cleaner reading than comparing it with the preceding quarter, since seasonal patterns affect many businesses in India.
Final Take: Which Stock Has the Strongest Roadmap?
These three healthcare stocks cover fermentation ingredients, biologics and global generics. Concord Biotech leads on FY26 operating margin and return on equity; Shilpa Medicare leads on Q1 FY27 revenue growth; Aurobindo Pharma leads on the lowest P/E.
Across fermentation ingredient, biologics and global generic stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the fermentation ingredient, biologics and global generic stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Fermentation Ingredient, Biologics and Global Generic Stocks
Which are the best fermentation ingredient, biologics and global generic stocks in India with a strong roadmap?
Ans. Concord Biotech, Shilpa Medicare and Aurobindo Pharma stand out for their roadmaps in fermentation ingredients, biologics and global generics. Return on equity ranges from 9.25% to 12.94%.
Is Concord Biotech a good stock to buy now?
Ans. Concord Biotech has a debt to equity ratio of 0.00, a return on equity of 12.94% and a P/E of 51.00 against an industry P/E of 37.59. Valuation, growth and regulation move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of Concord Biotech, Shilpa Medicare and Aurobindo Pharma?
Ans. The P/E ratio is 51.00 for Concord Biotech (industry 37.59), 67.52 for Shilpa Medicare (industry 37.59) and 25.46 for Aurobindo Pharma (industry 37.59). Only Concord Biotech and Shilpa Medicare trade at or above the industry multiple.
Which of these fermentation ingredient, biologics and global generic stocks has the highest return on equity?
Ans. Concord Biotech has the highest return on equity at 12.94%, followed by Shilpa Medicare at 9.39% and Aurobindo Pharma at 9.25%.
What are the risks of investing in fermentation ingredient, biologics and global generic stocks?
Ans. The main risks are valuation, pricing rules, regulation and quarterly trends. Shilpa Medicare trades at 67.52 times earnings against an industry multiple of 37.59.
How did Concord Biotech, Shilpa Medicare and Aurobindo Pharma perform in Q1 FY27?
Ans. Concord Biotech reported revenue of Rs 270.32 crore, up 24.2% year on year, and net profit rose 31.0% to Rs 57.70 crore. Shilpa Medicare reported revenue of Rs 468.91 crore, up 43.0% year on year. Aurobindo Pharma reported revenue of Rs 9,414.58 crore, up 18.1% year on year, and net profit rose 25.2% to Rs 1,032.03 crore.
Do fermentation ingredient, biologics and global generic stocks pay dividends?
Ans. Yes, all three companies pay dividends. The dividend yield is 0.57% for Concord Biotech, 0.06% for Shilpa Medicare and 0.25% for Aurobindo Pharma, based on dividends declared for FY26.
How can I invest in fermentation ingredient, biologics and global generic stocks in India?
Ans. You can buy fermentation ingredient, biologics and global generic stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.
